Milagros Flores
@dramiliflores.bsky.social
Nephron lover | #NephEdC #NephJC #ISNSoMe team #ISNWCN #SLANHJoven #nefroneando avanzamos #butfirstcoffee ☕ Life traveler 🧳 🇭🇳🇲🇽🏳️🌈 🇬🇹🇸🇻🇺🇸🇪🇸🏴🇵🇹🇹🇷🇹🇭🇦🇷🇮🇹🇻🇦🇫🇷💥
MERCURI-2 has landed at #NephJC 🛬 📍Does it challenge the way we #flozinate before surgery? #nephsky #medsky VA by @manoleaandreea.bsky.social @nephjc.bsky.social
Nephrology Journal Club@nephjc.bsky.social · 2w agoExcited for SGLT2 inhibitors to prevent AKI in CV surgery patients? So were we... until we got past the title. This week we're talking about "that JAMA paper "🙃 #NephJC #NephSky Here's the VA by @ManoleaA www.nephjc.com/news/2026/8/17/mercuri-the-visual-abstract
Mercuri-2: ¿Qué significa administrar dapagliflozina justo antes de una cirugía cardíaca? 💊 4 dosis perioperatorias 🫀 Cirugía cardíaca electiva 📉 ↓46% riesgo relativo de LRA vs placebo Pero… ¿protección renal real? 🤔 En vivo por #NephJC #nephsky #medsky @nephjc.bsky.social @jamanetworkopen.com
Nephrology Journal Club@nephjc.bsky.social · 2w agoEl Resume Visual #NephJC #NephSky @manoleaandreea.bsky.social @dramiliflores.bsky.social www.nephjc.com/news/2026/8/17/mercuri-el-resumen-visual
#NephJC #TenPostNephJC FIND-CKD asks: Can we extend nsMRA cardiorenal benefits to the massive population with CKD without diabetes? Let’s FIND out! 🔍 Read the article 👇: pubmed.ncbi.nlm.nih.gov/42246672/ 1/10🧵
A un mes del #era26 🛬 Hoy es el turno de FIND-CKD 🫰 ¿Está la finerenona lista para ir más allá de la nefropatía diabética? Estrenamos resumen visual, elaborado por Raquel Barba 🇪🇸 #nephjc #nefroneando avanzamos #medsky #nephsky
Nephrology Journal Club@nephjc.bsky.social · last mo.¿Está la finerenona lista para ir más allá de la diabetes? El resumen visual @drbarbateba.bsky.social @dramiliflores.bsky.social #NephJC #NephSky www.nephjc.com/news/2026/7/17/find-ckd-el-resumen-visual
Meeting number 2 is in the books. 🧑🏫We reviewed how to blog, create a VA, create a post thread and promote on Insta. So many ways to learn and teach #NephJC #NephSky @dramiliflores.bsky.social @drpallaviprasad.bsky.social @nephroseeker.medsky.social @hswapnil.medsky.social @brianrifkin.bsky.social
El resumen visual by @dramiliflores.bsky.social #NephJC #NephTwitter (Que lastima lo de Mexico ⚽️🥅, la proxima sera) www.nephjc.com/news/2026/7/6/track-el-resumen-visual
Track: El Resumen Visual — NephJC
¿Puede rivaroxabán reducir los eventos cardiovasculares en la ERC avanzada? El estudio TRACK comparó rivaroxabán a dosis bajas frente a placebo en pacientes con ERC estadio 4–5 y enfermedad renal en ...
nephjc.com
#NephJC Shorts is our new way to share quick takes on notable studies we can’t cover fully 👇👇Check the updated blog page for upcoming Shorts and those already published ✨Suggestions and feedback welcome www.nephjc.com/nephjc-shorts
NephJC Shorts — NephJC
nephjc.com
𝗜𝗦𝗡 𝗩𝗜𝗗𝗘𝗢 𝗔𝗕𝗦𝗧𝗥𝗔𝗖𝗧 𝗦𝗘𝗥𝗜𝗘𝗦: Infliximab for Grade III or IV Immune Checkpoint Inhibitor Nephritis Clinical & Translational Evidence. 2026, @kireports.bsky.social https://www.kireports.org/article/S2468-0249(25)00662-X/fulltext #VideoAbstract: @dramiliflores.bsky.social & @drsumanbehera.bsky.social
Welcome to #nephjc
Nephrology Journal Club@nephjc.bsky.social · 2mo ago🦵Had our Kick-off meeting today to welcome a new class of #NephJC interns (year 12 and counting). 👁️Keep an eye out for new blog and VA creators. See if you can Catch'em All🎣 #NephSky #MedSky @hswapnil.medsky.social @kidneyboy.bsky.social @nephroseeker.medsky.social @dramiliflores.bsky.social
See the #NephjC summary from @jamiekwillows.bsky.social www.nephjc.com/news/2026/06... cc @juancarlosqvelez.bsky.social @brycebarr.bsky.social
Heir to the Throne? Obinutuzumab in the membranous nephropathy MAJESTY trial — NephJC
This week, NephJC will discuss whether obinutuzumab is ready to outperform tacrolimus in primary membranous nephropathy
nephjc.com
The MAJESTRY trial, OBI vs TAC in membranous nephropathy. 👑 Visual abstract by Dr. Divya Bajpai #NephSky #NephJC www.nephjc.com/news/majestytrial
Majesty: The Visual Abstract — NephJC
Fresh from the #ERA26 Late-Breaking Clinical Trials, the MAJESTY study compared obinutuzumab with tacrolimus and raises important questions about the future of anti-CD20 therapy. 👑 Is deeper B-cell d...
nephjc.com
📢 Recién llegado desde #ERA26, el estudio MAJESTY comparó obinutuzumab frente a tacrolimus y plantea importantes interrogantes sobre el futuro de las terapias anti-CD20 en la nefropatía membranosa primaria #nephsky #medsky #nephjc
Nephrology Journal Club@nephjc.bsky.social · 2mo ago1/10 With the incredible wave of glomerular disease and trials showcased at #ERA26, it's time for membranous nephropathy to take the stage Could deeper B-cell depletion finally claim the throne? 👑 Read the article 👇 pubmed.ncbi.nlm.nih.gov/42246654/ #NephJC #TenPostNephJC #NephSky
Is it time for a new leader in membranous nephropathy, or is it just a game of thrones 👑? This week we're discussing OBI vs TAC in the MAJESTRY trial from #ERA26 🏰🐑 #NephSky We welcome back from retirement @jamiekwillows.bsky.social with the summary ✍️ www.nephjc.com/news/2026/06/22-majestyobi
Heir to the Throne? Obinutuzumab in the membranous nephropathy MAJESTY trial — NephJC
This week, NephJC will discuss whether obinutuzumab is ready to outperform tacrolimus in primary membranous nephropathy
nephjc.com
🚨New 🩳 by @nephroseeker.medsky.social eGFRcr, eGFRcys, eGFRcr-cys, mGFR... What does mGFR teach us about estimates and outcomes? #NephSky #MedSky #NephJC www.nephjc.com/news/2026/short/measuredgfr
NephJC Short: The map and the territory: what measured GFR teaches us about our estimates — NephJC
Is measured GFR more accurate than eGFR for forecasting adverse outcomes?
nephjc.com
10/10 Final thoughts: ✈️🚉🚗 we made it to #ERA26, sorry we're a little late on the posts! @nephroseeker.medsky.social Renal biopsy in diabetics is still a gold standard to rule out NDKD and improve the survival in diabetic patients… Up next, LBCT from #ERA26 Join us at nephjc.com
#TenPostNephJC #NephSky #NephJC 1/10 How often do we miss non-diabetic kidney disease (NDKD)? 🚩NDKD are 1) active urine sediment, 2) sudden worsening RFT, 3) absence of retinopathy 4) systemic symptoms like rash @glombandit.bsky.social kidney-international.org/article/S008...
✨Exciting news #NephtSky The new #NephJC editorial interns are here! 📢Give them a follow and make them feel at home 👉 @drbarbateba.bsky.social @ancast13.bsky.social @kiddokidney.bsky.social @andrewdelaat.bsky.social @farahwehbe92.bsky.social 👇👇 www.nephjc.com/news/2025/6/...
NephJC Internship 2026-2027 — NephJC
Introducing NephJC’s brand new editorial internship class of 2026-2027
nephjc.com
Hypertension control remains stubbornly low in underserved communities. IMPACTS‑BP asks whether a team‑based, multi‑component approach can meaningfully improve BP control and adherence in low‑income patients 🎨 #VisualAbstract by @nephromommy-akshu.bsky.social www.nephjc.com/news/2026/5/...
10/10 Final thoughts New drug, more data= good. Keep an eye out for data manipulation & always be a little skeptical. ➡️Up next May 19, 2026: Multifaceted Strategies for Hypertension Control in Low-Income Patients (Mills et al, NEJM, 2026) Join us www.nephjc.com/ How we doing?
9/10 I want more info: Blog by @sayalibthakare.bsky.social @drsaivani.bsky.social www.nephjc.com/news/trcpc6inhibition-fsgs VA by Dr. Divya Bajpai www.nephjc.com/news/2026/5/3/trpc6-inhibition-the-visual-abstract
TRPC6 inhibition: The Visual Abstract — NephJC
For the first time, a podocyte-targeted therapy shows clinical efficacy in FSGS. This week #NephJC covers the phase 2 RCT of BI 764198, an oral TRPC6 inhibitor that lowered proteinuria, preserved eGFR...
nephjc.com
8/10 #NephJC Consensus 1️⃣BI 764198 administration in 1° FSGS caused a modest ⬇️UPCR 2️⃣Unclear if this will lead to better eGFR outcomes in a heterogenous group of FSGS pts 3️⃣Appears most helpful in genetic FSGS with TRPC6 mutations
5/10 A figure paints🖼️ a 1000 words! This figure is… a lot. Full analysis & per protocol sets at various doses Small # in each group A) 1° endpoint: 25% ⬇️ UPCR from baseline D) Proportion achieving a UPCR of <1 g/g E) Δ in 24 h UPCR in pts with confirmed TRPC6
4/10 One post results Of the 60 pts: 1° endpoint (≥ 25% ⬇️ in UPCR from baseline at week 12) was seen in 7% of placebo vs 35% of all BI 764198 dose groups OR 4.9 [95% CI 1.0–48.8]
3/10 One post methods Phase 2, multicentric/multinational, parallel-group, placebo controlled RCT Primary FSGS or genetic FSGS resulting from a TRPC6 variant. Patients were given 20/40/80 mg of study drug
2/10 What'd I miss? TRPC6 mutation was found in a family with FSGS in 2005 Variant ⬆️ in intracellular iCa= crucial signaling mechanisms ➡️ detachment & apoptosis of podocytes 💥 Presents in the 3rd-4th decade with proteinuria & rapidly progressive CKD
1/10 #NephJC #TenPost #NephSky In 2026 the only FDA approved 💊 for FSGS is sparsentan, an endothelin A/angiotensin II receptor inhibitor. Next up in the pipeline…transient receptor potential cation channel 6 (TRPC6) inhibitor (BI 764198) 🚰 Read the article 👇 www.pubmed.ncbi.nlm.nih.gov/41616795/
Gracias @dramiliflores.bsky.social, el resumen visual en espanol #NephSky #MedSky www.nephjc.com/news/2026/trpc6-spanish
Inhibidor de TRPC6: El Resumen Visual — NephJC
Por primera vez, una terapia dirigida al podocito muestra eficacia clínica en GEFyS. Esta semana #NephJC revisa el ECA fase 2 de BI 764198, inhibidor oral de TRPC6, que redujo proteinuria, estabilizó ...
nephjc.com
Do you struggle with FSGS? Are you a sparsentan fan but asking, what's next? TRPC6 inhibitors completed a phase 2 study! Are we closing in on a common pathway of FSGS pathology? Blog by @drsaivani.bsky.social & @sayalibthakare.bsky.social #NephSky #MedSky www.nephjc.com/news/trcpc6inhibition-fsgs
Is TRPC6 inhibition for FSGS a trick or a treat? — NephJC
This week, we will discuss a phase 2 trial of the TRPC6 inhibitor BI 764198 in FSGS—an early signal for a podocyte-targeted therapy showing proteinuria reduction but set against small numbers, heterog...
nephjc.com
